ASCO GU 2019 Kidney Cancer - Results from #40

Viewing 41-52 of 52 articles

ASCO GU 2019: The UCLA Histo-Genetic Risk Classification (U-HGRC) to Predict Outcomes of Localized Clear Cell Renal Cell Carcinoma

ASCO GU 2019: Alterations in DNA Damage Repair Genes and Outcomes to Systemic Therapy in Immune-oncology versus Tyrosine Kinase Inhibitor Treated Metastatic Clear Cell Renal Cell Carcinoma Patients

ASCO GU 2019: Analysis of Overall Survival Based on Early Tumor Shrinkage in the Phase III METEOR Study of Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma

ASCO GU 2019: Genetic Evolution of Metastatic Renal Cell Cancer

ASCO GU 2019: Results of a Phase II Study of Atezolizumab and Bevacizumab in Non-clear Cell Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma with Sarcomatoid Differentiation

ASCO GU 2019: Thirty Month Follow-up of the Phase III CheckMate 214 Trial of First-line Nivolumab + Ipilimumab or Sunitinib in Patients with Advanced Renal Cell Carcinoma

ASCO GU 2019: First-Line Systemic Therapy in the Patient With Intermediate-or Poor-Risk Disease: What Agent Should It be in 2019?

ASCO GU 2019: TIVO-3: Tivozanib Compared to Sorafenib in Patients with Refractory Advanced Renal Cell Carcinoma (RCC)

ASCO GU 2019: Beyond First-Line Systemic Therapy for Metastatic Renal Cell Cancer

ASCO GU 2019: CheckMate 214 Trial - Thirty Month Follow-up of First-line Nivolumab + Ipilimumab or Sunitinib in Patients with Advanced Renal Cell Carcinoma

ASCO GU 2019: Alterations in DNA Damage Repair Genes and Outcomes to Systemic Therapy in IO versus TKI Treated Metastatic Clear Cell Renal Cell Carcinoma Patients

ASCO GU 2019: Early Tumor Shrinkage in the Phase III METEOR Study of Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma - An Analysis of Overall Survival

1
2
3